Anticancer drug prices and clinical outcomes: a cross-sectional study in Italy

Menée dans un contexte italien, cette étude rétrospective analyse le rapport coût-efficacité de 30 médicaments anticancéreux autorisés par l'Agence européenne des médicaments entre 2010 et 2016

Résumé en anglais

Objective :To investigate whether the prices of new anticancer drugs correlated with their relative benefit despite negotiation.

Design :Retrospective cross-sectional study correlating new anticancer drugs prices with clinical outcomes.

Setting :We did a retrospective cross-sectional study including all new anticancer drugs approved by the European Medicines Agency (EMA) (2010–2016) and reimbursed in Italy.

Main outcome(s) and measure(s) :Information on clinical outcomes—in terms of median overall survival (OS), median progression-free survival (PFS) and objective response rate (ORR)—was extracted from pivotal trials as reported in the European Public Assessment Reports available on the EMA website. Cost of a full course treatment was estimated on negotiated official and discounted prices. Regression coefficients